



Altimune to Participate in Two Upcoming Investor Conferences

September 23, 2025 at 7:30 AM EDT

GAITHERSBURG, Md., Sept. 23, 2025 (GLOBE NEWSWIRE) -- [Altimune, Inc.](#) (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and cardiometabolic diseases, today announced that members of the Company's management team will participate and be available for 1x1 meetings at the following investor conferences:

- **Stifel 2025 Virtual Cardiometabolic Forum**
Tuesday, September 30, 2025
Fireside Chat at 10:30 a.m. Eastern Time
- **H.C. Wainwright Liver Disease Virtual Conference**
Tuesday, October 21, 2025
Fireside Chat at 7:00 a.m. Eastern Time

The sessions will be webcast and can be accessed by visiting the [Events](#) section of the Altimune website.

About Altimune

Altimune is a late clinical-stage biopharmaceutical company focused on developing novel peptide-based therapeutics for liver and cardiometabolic diseases. The Company's lead product candidate is pemvidutide, a GLP-1/glucagon dual receptor agonist for the treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH), Alcohol Use Disorder (AUD), Alcohol-associated Liver Disease (ALD) and obesity. For more information, please visit www.altimmune.com.

Follow [@Altimune, Inc. on LinkedIn](#)

Follow [@AltimuneInc on X](#)

Investor Contact:

Lee Roth

Burns McClellan

Phone: 646-382-3403

lroth@burnsmc.com

This press release was published by a CLEAR® Verified individual.



altimmune

Source: Altimune, Inc